Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits

Study concluded allograft and autograft repairs delivered significantly better rates of meaningful sensory recovery in short gaps as compared to conduit repairs in a systematic meta-analysis including over 1,500 nerve repairs across 35 studies

ALACHUA, Fla. and TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the independent publication of a comprehensive, retrospective clinical review comparing the meaningful recovery rates between allograft, autograft, and conduits using a meta-analysis methodology. The comparative peer-reviewed analysis was published online ahead of print by Plastic and Reconstructive Surgery. The publication, “A systematic review and meta-analysis of nerve gap repair: Comparative effectiveness of allografts, autografts, and conduits,” analyzed 35 peer-reviewed studies with a total of 1,559 nerve repairs including 711 nerve allograft, 670 autograft, and 178 conduit repairs.

• The analysis concluded that meaningful recovery rates for allograft and autograft repairs were comparable across all gap lengths up to 70 millimeters.
• There were no statistical differences between allograft and autograft outcomes for either short (5-30 mm) or long (31-70 mm) gap lengths for both sensory and motor repairs.
• Allograft and autograft repairs delivered significantly better rates of meaningful sensory recovery in short gaps as compared to conduit repairs; 87.1% and 81.6% vs. 62.2%, respectively, p